ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2387

Response to Pamidronate Treatment Assessed By Whole Body Magnetic Resonance Imaging in Pediatric Chronic Non-Bacterial Osteomyelitis

Caroline Marie Andreasen1, Anne Grethe Jurik2, Mia Glerup3, Christian Høst4, Birgitte Thorsted Mahler4, Ellen-Margrethe Hauge5 and Troels Herlin6, 1Dept. Rheumatology, Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 2Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, 3Pediatric Rheumatology Clinic, Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, 4Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Bisphosphonates, Chronic recurrent multifocal osteomyelitis (CRMO), magnetic resonance imaging (MRI) and pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Pamidronate (PAM) may be effective in diminishing pain and permanent bone deformities in chronic non-bacterial osteomyelitis (CNO). Whole body magnetic resonance imaging (WB MRI) can be used to assess anatomical site, extent and inflammatory activity of bone lesions. The aim of this study was to evaluate the clinical and radiological outcome of children with CNO after one year of PAM treatment.

Methods: A retrospective evaluation of children diagnosed with CNO according to the Bristol criteria ADDIN RW.CITE{{216 Roderick,M. 2014}}(1). Children were treated with i.v. PAM 1mg/kg (max 60 mg/day) for 3 consecutive days every 3 months. We included 17 children (8 girls and 9 boys) median age 11 years (range 5-13). Medical history, clinical assessments and inflammatory biochemistry were obtained. WB MRI (1,5 Tesla) short tau inversion recovery (STIR) and T1-weighted images were performed at baseline, median -1 month (range -6-0) and after one year PAM treatment, median 12 months (range 9-19). Number of bone lesions are listed per patient (median, range).

Results: Comorbidities were JIA (n=3) and IBD (n=1); none of the children had psoriasis. All children had been treated with NSAID as first line treatment. Further medical history was antibiotics (n=1), methotrexate (n=7), steroids (n=7) and anti-TNFα treatment (n=3). Six children had elevated sedimentation rate at baseline, which normalized after one year.  At baseline there were in total 52 clinical symptomatic lesions, median 3 (range 1-8) and 113 radiological active lesions, median 6 (range 2-14). The most common sites of bone lesions were femur (19%), tibia (19%) and spine (12%). Six children had spinal lesions, median 1 (range 1-4), and 5 children had non-erosive lesions in relation to the sacroiliac (SI)-joints. After one year 11 children were still radiological active based on MRI with total number of 68 lesions, median 4 (range 1-21) (Table 1). Only one active spinal and one SI-joint lesion persisted. Ten children had new or worsening of lesions, median 2 (range 1-15). Three children had deformation of 11 vertebral bones (10 thoracic, 1 cervical) without sign of active inflammation. After one year the clinical symptoms in the radiological active group were; five with total pain relief, 5 with partial pain relief and 2 without any pain relief. In 6 children lesions resolved completely as assessed by MRI, but pain was still reported in 4 of them.

Conclusion: PAM given for one year is a potent second-line treatment for CNO. Axial lesions and SI-joint lesions respond well to PAM. Persistent pain or pain progression may exist despite total resolution as assessed by WB MRI. ADDIN RW.BIB (1) Roderick M. Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging. Rheumatology (Oxford) 2014; 53(11):1973-1976  

Tab. 1. Distribution and number of active bone lesions before and after pamidronate treatment

Baseline

Year 1

Number of bone lesions n (%)

Number of children affected

Number of bone lesions n (%)

Number of children affected

Clavicle

1 (1)

1

1 (2)

1

Scapula

3 (3)

2

2 (3)

1

Humerus

5 (4)

3

3 (4)

1

Radius

2 (2)

1

0 (0)

0

Femur

21 (19)

10

10 (15)

6

Tibia

22 (19)

10

13 (19)

7

Fibula

3 (3)

2

2 (3)

1

Talus

1 (1)

1

0 (0)

0

Calcaneus

5 (4)

4

0 (0)

0

Feets (other)

8 (7)

4

3 (4)

2

Metatars

7 (6)

5

19 (28)

4

Spine

14 (12)

6

1 (2)

1

SI-joint

6 (5)

5

2 (3)

2

Pelvis

13 (12)

5

8 (12)

4

Mandible

2 (2)

1

2 (3)

1

Patella

0 (0)

0

2 (3)

1

Total

113

17

68

11


Disclosure: C. M. Andreasen, None; A. G. Jurik, None; M. Glerup, None; C. Høst, None; B. Thorsted Mahler, None; E. M. Hauge, None; T. Herlin, None.

To cite this abstract in AMA style:

Andreasen CM, Jurik AG, Glerup M, Høst C, Thorsted Mahler B, Hauge EM, Herlin T. Response to Pamidronate Treatment Assessed By Whole Body Magnetic Resonance Imaging in Pediatric Chronic Non-Bacterial Osteomyelitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/response-to-pamidronate-treatment-assessed-by-whole-body-magnetic-resonance-imaging-in-pediatric-chronic-non-bacterial-osteomyelitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/response-to-pamidronate-treatment-assessed-by-whole-body-magnetic-resonance-imaging-in-pediatric-chronic-non-bacterial-osteomyelitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology